Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 16/20 | 0.41 |
| ▸ | JAK2 | O60674 | 13/20 | 0.41 |
| ▸ | JAK1 | P23458 | 11/20 | 0.41 |
| ▸ | TYK2 | P29597 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22370627 | 0.90 | JAK2 (0.38) | ALDH1A1MEN1MAPTKMT2AJAK3 | |
| SCHEMBL18525632 | 0.81 | CHRM2 (0.44) | ALDH1A1MEN1MAPTKMT2AJAK3 | |
| SCHEMBL13724137 | 0.80 | JAK3 (0.44) | ALDH1A1MEN1MAPTKMT2AJAK3 | |
| SCHEMBL14426034 | 0.80 | ALDH1A1 (0.63) | ALDH1A1MEN1MAPTKMT2ALMNA | |
| SCHEMBL22620113 | 0.80 | JAK3 (0.44) | ALDH1A1MEN1MAPTKMT2AJAK3 | |
| SCHEMBL14644693 | 0.80 | ALDH1A1 (0.63) | ALDH1A1MEN1MAPTKMT2ALMNA | |
| SCHEMBL12957767 | 0.80 | ALDH1A1 (0.63) | ALDH1A1MEN1MAPTKMT2ALMNA | |
| SCHEMBL21729624 | 0.80 | JAK3 (0.39) | ALDH1A1MEN1MAPTKMT2AJAK3 | |
| SCHEMBL22370790 | 0.79 | JAK2 (0.47) | ALDH1A1MEN1MAPTKMT2AJAK3 | |
| SCHEMBL22370793 | 0.79 | JAK2 (0.47) | ALDH1A1MEN1MAPTKMT2AJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407430-B2 | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | YANG JI CHEMICAL CO., LTD. (KR) | 2019-09-10 | — | — | US | claimed |
| US-20180237440-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | YANG JI CHEMICAL CO., LTD. (KR) | 2018-08-23 | — | — | US | claimed |
| EP-3327021-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | Yangji Chemical Co., Ltd. (KR) | 2018-05-30 | — | — | EP | claimed |
| CN-108137608-B | Janus kinase 1 selective inhibitor and pharmaceutical application thereof | 阳智化学（株） | 2020-06-19 | — | — | CN | disclosed |
| US-10407430-B2 | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | YANG JI CHEMICAL CO., LTD. (KR) | 2019-09-10 | — | — | US | disclosed |
| US-20180237440-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | YANG JI CHEMICAL CO., LTD. (KR) | 2018-08-23 | — | — | US | disclosed |
| EP-3327021-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | Yangji Chemical Co., Ltd. (KR) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407430-B2 | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | JAK1, JAK2, JAK3 | ALDH1A1 937/4885MEN1 655/4885MAPT 2641/4885 |
| US-20180237440-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | JAK1, JAK2, JAK3 | ALDH1A1 1938/4885MEN1 1074/4885MAPT 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.